02:22 PM EDT, 08/12/2024 (MT Newswires) -- Oragenics ( OGEN ) shares surged nearly 16% in recent Monday trading after the company said its concussion treatment candidate, dubbed ONP-002, has completed a study showing it does not cause deoxyribonucleic acid, or DNA, damage or genotoxicity in animals.

The study tested ONP-002 over several days in low, medium, and high doses. The results showed no genetic mutations, indicating that ONP-002 does not affect the cell cycle or disrupt cell division which could increase cancer risk, the company said.

The study suggests that multi-day treatment for concussion using ONP-002 will not cause genetic harm, the company added.

"Oragenics ( OGEN ) strongly believes that ONP-002 will be safe for concussed patients in our planned phase 2 clinical trial," Oragenics ( OGEN ) President Michael Redmond said.

Price: 1.62, Change: +0.22, Percent Change: +15.71